- $2.72bn
- $2.65bn
- $305.45m
- 68
- 17
- 99
- 65
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 77.93 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 11.11 | ||
| Price to Tang. Book | 31.44 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.92 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -6.37% | ||
| Return on Equity | -22.1% | ||
| Operating Margin | -7.6% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 179.32 | 212.19 | 234.69 | 202.57 | 305.45 | 358.94 | 425.02 | 9.26% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +106.24 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through the GeneDx segment. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. It provides carrier/variant-specific testing, targeted mosaic variant testing, and others.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 10th, 2020
- Public Since
- September 4th, 2020
- No. of Employees
- 1,000
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 28,531,642
- Address
- 333 Ludlow Street, STAMFORD, 06902
- Web
- https://sema4.com/
- Phone
- +1 6177808742
- Auditors
- Ernst & Young LLP
Upcoming Events for WGS
Q1 2025 GeneDx Holdings Corp Earnings Release
GeneDx Holdings Corp Annual Shareholders Meeting
Q2 2025 GeneDx Holdings Corp Earnings Release
Similar to WGS
Acadia Healthcare
NASDAQ Global Select Market
Addus HomeCare
NASDAQ Global Select Market
Alignment Healthcare
NASDAQ Global Select Market
Amedisys
NASDAQ Global Select Market
Aveanna Healthcare Holdings
NASDAQ Global Select Market
FAQ
What is the GeneDx Holdings share price?
As of Today at 20:46 UTC, shares in GeneDx Holdings are trading at $95.47. This share price information is delayed by 15 minutes.
How has the GeneDx Holdings share price performed this year?
Shares in GeneDx Holdings last closed at $95.47 and the price had moved by +937.72% over the past 365 days. In terms of relative price strength the GeneDx Holdings share price has outperformed the S&P500 Index by +875.75% over the past year.
What are the analyst and broker recommendations for GeneDx Holdings?
The overall consensus recommendation for GeneDx Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the GeneDx Holdings dividend yield?
GeneDx Holdings does not currently pay a dividend.
Does GeneDx Holdings pay a dividend?
GeneDx Holdings does not currently pay a dividend.
When does GeneDx Holdings next pay dividends?
GeneDx Holdings does not currently pay a dividend.
How do I buy GeneDx Holdings shares?
To buy shares in GeneDx Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of GeneDx Holdings?
As of the previous close price of $95.47, shares in GeneDx Holdings had a market capitalisation of $2.72bn.
Where are GeneDx Holdings shares listed?
Here are the trading details for GeneDx Holdings:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: WGS
What kind of share is GeneDx Holdings?
Based on an overall assessment of its quality, value and momentum GeneDx Holdings is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a GeneDx Holdings share price forecast for 2025?
The analyst consensus target price for shares in GeneDx Holdings is $107.83. That is 12.95% above the last closing price of $95.47.
Analysts covering GeneDx Holdings currently have a consensus Earnings Per Share (EPS) forecast of $0.93 for the next financial year.
Find out moreWhat is the trend in the GeneDx Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like GeneDx Holdings. Over the past six months, its share price has outperformed the S&P500 Index by +76.18%.
As of the last closing price of $95.47, shares in GeneDx Holdings were trading +46.96% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the GeneDx Holdings PE Ratio?
The GeneDx Holdings PE ratio based on its reported earnings over the past 12 months is 77.93. The shares last closed at $95.47.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of GeneDx Holdings?
We do not have data on GeneDx Holdings' directors